DE69510190T2 - Verwendung von fettsäureester als bioklebstoffe - Google Patents

Verwendung von fettsäureester als bioklebstoffe

Info

Publication number
DE69510190T2
DE69510190T2 DE69510190T DE69510190T DE69510190T2 DE 69510190 T2 DE69510190 T2 DE 69510190T2 DE 69510190 T DE69510190 T DE 69510190T DE 69510190 T DE69510190 T DE 69510190T DE 69510190 T2 DE69510190 T2 DE 69510190T2
Authority
DE
Germany
Prior art keywords
fatty acid
acid esters
mucosa
bioadhesive
glyceryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69510190T
Other languages
English (en)
Other versions
DE69510190D1 (de
Inventor
Jens Hansen
Nielsen Lise Sylvest
Tomas Norling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandberg Development AB
Original Assignee
GS Development AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GS Development AB filed Critical GS Development AB
Publication of DE69510190D1 publication Critical patent/DE69510190D1/de
Application granted granted Critical
Publication of DE69510190T2 publication Critical patent/DE69510190T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69510190T 1994-03-30 1995-03-29 Verwendung von fettsäureester als bioklebstoffe Expired - Fee Related DE69510190T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK37094 1994-03-30
PCT/DK1995/000143 WO1995026715A2 (en) 1994-03-30 1995-03-29 Use of fatty acid esters as bioadhesive substances

Publications (2)

Publication Number Publication Date
DE69510190D1 DE69510190D1 (de) 1999-07-15
DE69510190T2 true DE69510190T2 (de) 2000-01-27

Family

ID=8092745

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69510190T Expired - Fee Related DE69510190T2 (de) 1994-03-30 1995-03-29 Verwendung von fettsäureester als bioklebstoffe

Country Status (12)

Country Link
US (1) US5955502A (de)
EP (1) EP0752855B1 (de)
JP (1) JP4137179B2 (de)
AT (1) ATE180971T1 (de)
AU (1) AU685262B2 (de)
CA (1) CA2186750C (de)
DE (1) DE69510190T2 (de)
DK (1) DK0752855T3 (de)
ES (1) ES2135723T3 (de)
FI (1) FI963867A (de)
NO (1) NO964113L (de)
WO (1) WO1995026715A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018129419A1 (de) 2018-11-22 2020-05-28 Johannes Gutenberg-Universität Mainz Acrylat-Copolymer für galenische Anwendungen

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013528A1 (en) * 1995-10-12 1997-04-17 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
ATE246039T1 (de) * 1997-09-09 2003-08-15 Select Release L C Beschichtete teilchen, methode zu ihrer herstellung und verwendung
HUP0101248A2 (hu) * 1998-03-20 2001-08-28 Kowa Co., Ltd. Gyomor- és/vagy nyombél-adhezív gyógyászati készítmények
ITMI981528A1 (it) * 1998-07-03 2000-01-03 Recordati Ind Chimica E Farma Formulazioni topiche di aciclovir
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
PT1183014E (pt) 1999-06-14 2003-12-31 Cosmo Spa Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
KR100381622B1 (ko) * 2000-08-30 2003-04-26 디디에스텍주식회사 자극성을 줄인 염기성 약물의 구강 투여 조성물
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
US6887493B2 (en) * 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
NZ530439A (en) * 2001-04-20 2004-11-26 Lavipharm Lab Inc Intraoral delivery of nicotine for smoking cessation
DK1389137T3 (da) * 2001-05-21 2006-10-30 Injet Digital Aerosols Ltd Sammensætninger til lungelægemiddellevering af protein
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
CA2466432A1 (en) * 2001-11-08 2003-05-15 Atrium Medical Corporation Intraluminal device with a coating containing a therapeutic agent
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
ATE460206T1 (de) * 2003-07-01 2010-03-15 Skinsure Internat Ltd Barriereformulierung mit einer emulsion auf silikonbasis
US20050084471A1 (en) * 2003-09-09 2005-04-21 3M Innovative Properties Company Concentrated antimicrobial compositions and methods
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
BRPI0414193A (pt) * 2003-09-09 2006-10-31 3M Innovative Properties Co composição antimicrobiana, kit antimicrobiano e métodos de usar a composição e de aplicar uma composição antimicrobiana a um substrato
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
SG173326A1 (en) * 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
WO2006036969A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Formation of barrier layer
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
WO2006036970A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Method of thickening a coating using a drug
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
WO2006036982A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
DE602005026998D1 (de) 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
DK1845942T3 (da) * 2005-01-14 2014-04-28 Camurus Ab GNRH-analogformuleringer
US9649382B2 (en) * 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US9060935B2 (en) * 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
US10918618B2 (en) 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
CN101137359B (zh) 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
MX2007010904A (es) * 2005-03-10 2007-12-05 3M Innovative Properties Co Panuelo para mascota antimicrobiano.
MX2007010908A (es) 2005-03-10 2007-12-05 3M Innovative Properties Co Composiciones antimicrobianas que comprenden esteres de acidos hidroxicarboxilicos.
DK1888031T3 (da) * 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
US20080219935A1 (en) * 2005-07-08 2008-09-11 Sang-Hoon Kwak Phase Transitive Breath Care Products
US20070020228A1 (en) * 2005-07-22 2007-01-25 Williams Terry N Method of using a biosealant device
KR20080025761A (ko) * 2005-07-29 2008-03-21 더 제너럴 하스피탈 코포레이션 피부 손상을 감소시키는 방법 및 조성물
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
AU2006304590A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
MX2008006888A (es) 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.
EP1837020A1 (de) 2006-03-24 2007-09-26 Bioalliance Pharma Bioadhäsive Schleimhautträger zur langsamen Verabreichung von aktiven Substanzen
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US7772213B2 (en) * 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
WO2008057328A2 (en) 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
EP2101735A2 (de) 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoteilchenförmige formulierungen und verfahren zur herstellung und verwendung
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
US20090196905A1 (en) * 2008-02-06 2009-08-06 Spada Lon T Stabilization of mitochondrial membranes in ocular diseases and conditions
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
CA2790248A1 (en) 2010-03-15 2011-09-22 Ferrosan Medical Devices A/S A method for promotion of hemostasis and/or wound healing
US20130079371A1 (en) * 2010-04-01 2013-03-28 Pharmanest Ab Bioadhesive Compositions of Local Anaesthetics
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
EP2685962A1 (de) 2011-03-17 2014-01-22 Transdermal Biotechnology, Inc. Topische stickoxidsysteme sowie verfahren zu ihrer verwendung
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US9555118B2 (en) * 2011-12-05 2017-01-31 Camrus Ab Robust controlled-release peptide formulations
WO2013121429A1 (en) 2012-02-16 2013-08-22 Ramot At Tel-Aviv University Ltd. Formulations and kits for forming bioadhesive matrices
US11672843B2 (en) 2012-05-25 2023-06-13 Camurus Ab Somatostatin receptor agonist formulations
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US8889655B2 (en) 2012-07-20 2014-11-18 Aegis Women's Health Technologies Compositions and methods for preventing infectious diseases in females
PL2877155T3 (pl) 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271731A1 (en) * 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271938A1 (en) * 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
BR112015027026A8 (pt) * 2013-04-26 2018-01-30 Bioglan Ab composição para uso na redução da formação de casca e na promoção da cicatrização
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
EP4233861A3 (de) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Zusammensetzungen zur behandlung von essentiellem tremor
JP7064612B2 (ja) * 2018-09-20 2022-05-10 富士フイルム株式会社 生体材料
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
US11590151B2 (en) * 2019-08-30 2023-02-28 USpharma Ltd Pharmaceutical paste formulations for site specific application
CN114828889A (zh) 2019-12-06 2022-07-29 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
CN113350573B (zh) * 2021-06-07 2022-05-27 王健 一种具有骨诱导能力的多孔微球粘接剂及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062667B2 (ja) * 1986-04-11 1994-01-12 積水化学工業株式会社 貼付剤
JPS63101316A (ja) * 1986-10-16 1988-05-06 Nichiban Co Ltd 医療用製剤
JP3046330B2 (ja) * 1990-07-16 2000-05-29 日東電工株式会社 貼付製剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018129419A1 (de) 2018-11-22 2020-05-28 Johannes Gutenberg-Universität Mainz Acrylat-Copolymer für galenische Anwendungen
WO2020104104A1 (de) 2018-11-22 2020-05-28 Johannes Gutenberg-Universität Mainz Acrylat-copolymere für galenische anwendungen

Also Published As

Publication number Publication date
CA2186750A1 (en) 1995-10-12
JP4137179B2 (ja) 2008-08-20
ES2135723T3 (es) 1999-11-01
ATE180971T1 (de) 1999-06-15
AU685262B2 (en) 1998-01-15
EP0752855A1 (de) 1997-01-15
NO964113L (no) 1996-11-27
DE69510190D1 (de) 1999-07-15
FI963867A0 (fi) 1996-09-27
CA2186750C (en) 2008-08-05
WO1995026715A2 (en) 1995-10-12
AU2255095A (en) 1995-10-23
EP0752855B1 (de) 1999-06-09
DK0752855T3 (da) 2000-01-03
WO1995026715A3 (en) 1995-11-16
JPH09510980A (ja) 1997-11-04
FI963867A (fi) 1996-11-27
US5955502A (en) 1999-09-21
NO964113D0 (no) 1996-09-27

Similar Documents

Publication Publication Date Title
DE69510190D1 (de) Verwendung von fettsäureester als bioklebstoffe
EA200300830A1 (ru) Незаменимые n-3 жирные кислоты в лечении сердечной недостаточности и сердечной декомпенсации
HUP0303881A2 (hu) Gyulladás kezelésére alkalmas zsíralkoholokat és zsírsav-észtereket tartalmazó gyógyszerkészítmények
ES2001512A6 (es) Procedimiento para la fabricacion de esteres totales y parciales del acido hialuronico
NO934768D0 (no) Sammensetning av L-DOPA-estere
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE15443T1 (de) Essbare, pharmazeutische zusammensetzungen und verfahren zur herstellung.
DE69317306T2 (de) Verfahren zur herstellung von pharmazeutische zusammensetzungen mittels ultraschall
ATE326867T1 (de) Freie aminosäure enthaltende zusammensetzung
WO1997039759A3 (en) Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
DE69805846T2 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
WO1987004926A3 (en) Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
ATE193006T1 (de) Verfahren zur stabilisation der polyungesättigten fettsäuren und verwendung dieser stabilisierten produkten in therapie und in kosmetologie
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE110723T1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
EP0346927A3 (de) N-substituierte 3-Piperidin-carbonsäure oder N-substituierte 3-Pyridin-carbonsäure und ihre Derivate
HUP0204097A2 (hu) Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására
HUP0004058A2 (hu) Készítmények és eljárások biológiai membránok permeabilitásának reverzibilis növelésére
TNSN92115A1 (fr) Succedanes de benzimidazoles, processus de leur preparation ainsi que de leur utilisation
KR870006081A (ko) 신규 16,17-아세탈치환 프레그난 21-오익 에시드유도체 및 그의 제조방법
EP0334281A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
DE69630876D1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
WO1999003456A3 (en) Method for prophylaxis or treatment of bone density loss
DE60003921D1 (de) Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung
MD940244A (ro) Derivaţi noi ai tetrazolului, procedeu de obţinere a lor şi compoziţie farmaceutică pe baza lor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee